drugset / Trial / NCT07331818

Luspatercept in Patients Affected With Rare Inherited Anemias

NCT07331818

Phase 2 Not yet recruiting 45 enrolled EuroBloodNet Association
NaSingle-groupOpen-labelTreatment

Summary

This is a prospective multicenter phase II basket trial evaluating Luspatercept in patients affected with rare inherited anemias

Timeline

Start
2026-01-15
Primary completion
2028-09
Completion
2029-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Luspatercept Protein / enzyme biologic 1 mg/kg Other

Indications